Blood test could identify lung cancer patients likely to respond to drug erlotinibMay 1st, 2010 - 1:38 pm ICT by ANI
Washington, May 1 (ANI): A simple blood test could identify lung cancer patients who will respond positively to the drug erlotinib, reveals a new study.
The researchers found that testing for the presence of specific cancer protein ‘fingerprints’ in the blood of lung cancer patients may be a useful means of identifying a subgroup whose tumours are more likely to shrink when treated with erlotinib, especially when other testing methods are unavailable.
Erlotinib is one of a class of drugs that specifically inhibits an important cell-surface molecule known as the epidermal growth factor receptor (EGFR), which is highly expressed in some forms of cancer, including lung cancer.
By blocking this receptor, drugs such as erlotinib aim to slow tumour growth and proliferation.
Prof David Carbone from Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, and Canadian colleagues analysed blood samples from the NCIC Clinical Trials Group (NCIC CTG) BR.21 study.
The study had shown that erlotinib improved survival compared to placebo in patients with advanced non-small-cell lung cancer who had already tried one or two other drugs.
In the new study, the researchers analysed blood samples that had been taken from some patients before they started treatment in the BR.21 study.
They performed this analysis on patients who received the drug and on patients who received the placebo, looking for specific proteomic profiles already known to predict outcomes in patients treated with EGFR-blockers.
“The bottom line is that the proteomic test –comparing ‘good’ and ‘poor’ profiles– was strongly prognostic in both erlotinib and placebo arms. Proteomics ‘good’ patients also had a significantly higher response rate than proteomics ‘poor’ patients,” said Carbone.
Carbone has noted that there are other methods available to analyse the EGFR pathway of lung cancers, including sequencing of the EGFR gene, or a technique known as fluorescence in-situ hybridization (FISH) to assess EGFR gene copy number, in which tumour tissue samples are directly studied under a microscope.
“FISH overall was a better predictor of benefit, but can only be done with adequate biopsy tissue, which was available in this study only in 22pct of patients. With the serum test, 99pct of patients had a successful determination of proteomic status,’ said Carbone.
“Thus, I think this test may be of potential value in identifying a subgroup of patients with a good prognosis and who are likely to have response to erlotinib; it may be of particular value for those in whom tumor tissue is inadequate or unavailable,” added Carbone.
The study was presented at the 2nd European Lung Cancer Conference in Geneva, Switzerland. (ANI)
- New treatment strategy effective for certain lung cancers - Mar 11, 2011
- Targeted cancer drug more effective after first-line treatment - Feb 28, 2011
- India-US team finds new therapy for pancreatic cancer - Dec 30, 2008
- Blood protein in lung cancer may help improve diagnosis, treatment - Mar 03, 2011
- 'Allergies linked to lower risk of brain tumours' - Aug 06, 2012
- New therapeutic target for pancreatic cancer found - Apr 19, 2009
- New technique offers fresh hope to lung cancer sufferers - Mar 22, 2011
- Urine test can detect cancers early - Jun 10, 2011
- Gold nanoparticles may help detect tumor cells in blood - Feb 12, 2011
- Electronic nose helps locate deadly tumour - Aug 02, 2012
- Chemo-Vandetanib combo effective for lung cancer treatment: Study - Jun 06, 2010
- Molecule key to non-smoking lung cancer identified - Jul 28, 2009
- Genes linked to aggressive breast cancer identified - Aug 17, 2010
- 'Low oxygen levels drive cancer growth' - May 06, 2012
- Mechanism involved in breast cancer's spread to bone uncovered - Feb 04, 2011
Tags: canadian colleagues, cancer center, cell lung cancer, clinical trials group, david carbone, egfr pathway, epidermal growth factor, epidermal growth factor receptor, erlotinib, growth factor receptor, lung cancer patients, lung cancers, nashville tennessee, ncic clinical trials group, ncic ctg, non small cell lung cancer, poor patients, protein fingerprints, small cell lung cancer, specific cancer